Michael S. Weiss - 08 Jan 2026 Form 4 Insider Report for TG THERAPEUTICS, INC. (TGTX)

Role
CEO, Director
Signature
/s/ Michael S. Weiss
Issuer symbol
TGTX
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
4
Filing time
09 Jan 2026, 17:16:39 UTC
Previous filing
07 Nov 2025
Next filing
20 Mar 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Michael S. Weiss filed Form 4 for TG THERAPEUTICS, INC. (TGTX) on 09 Jan 2026."

Quick Takeaways

  • This page summarizes Michael S. Weiss's Form 4 filing for TG THERAPEUTICS, INC. (TGTX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 09 Jan 2026, 17:16.

What Changed

  • Previous filing in this sequence was filed on 07 Nov 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
WEISS MICHAEL S CEO, Director 3020 CARRINGTON MILL BLVD, SUITE 475, MORRISVILLE /s/ Michael S. Weiss 09 Jan 2026 0001038977

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TGTX Common Stock Award $0 +622,000 +6.8% $0.000000 9,778,086 08 Jan 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period.
F2 Includes shares of restricted Common Stock, which vest over various time periods.

Sponsored